Basel biologist wins science prize for thalidomide insights
Structural biologist Nicolas Thomä has been awarded this year’s Otto Naegeli Prize for medical research, considered one of the most prestigious scientific awards in Switzerland.
This content was published on
3 minutes
Keystone-SDA/ts
Español
es
Un biólogo de Basilea gana el premio científico Otto Naegeli
German-born Thomä, from the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel, is particularly concerned in his research with the degradation of disease-causing proteins, the FMI said in a statementExternal link on Tuesday. He and his team showed how some small molecules contribute to targeted protein degradation by functioning as “molecular glues”.
“Such molecular glues have the potential to target proteins that were previously thought to be undruggable,” the FMI wrote.
Every two years, the Otto Naegeli Foundation awards the prizeExternal link to outstanding personalities in medical research. The prize was established in 1960 in memory of the Zurich researcher and lecturer of internal medicine, Otto Naegeli (1871-1938).
Worth CHF200,000, the prize is awarded to researchers in Switzerland with the aim of stimulating medical and biomedical research. It recognises outstanding work on new biological mechanisms of action or therapeutic approaches.
Research from Thomä’s laboratory explained how the molecular glue thalidomide and its analogues function at the molecular level.
From 1957 thalidomide, marketed by West German company Chemie Grünenthal, was used to treat nausea during pregnancy. It gained notoriety at the beginning of the 1960s when it was discovered that it caused birth defects, usually involving babies’ limbs, whereupon it was withdrawn from the market. Later, however, the active ingredient experienced a renaissance in the fight against various forms of blood cancer. This is because thalidomide can mark disease-causing proteins as waste and release them for degradation, which causes the cancer cells to die. This video explains how.
External Content
However, thalidomide can also interact with proteins that are important during embryonic development in the womb, which is probably the cause of the malformations.
New therapeutic drugs
The disclosed mechanism of action of thalidomide is groundbreaking for the next generation of therapeutic drugs, according to Thomä. The findings would also make it possible both to recognise and minimise undesirable side effects of drugs and to attack several disease-causing proteins simultaneously with one drug, he said.
Thomä said he would like to use the CHF200,000 ($210,000) prize money to develop a new generation of drugs based on the molecular glue principle. This is because many proteins behind diseases such as cancer, cardiovascular diseases or diabetes cannot yet be tackled with traditional methods, he explained.
Thomä, 50, has been working at the Friedrich Miescher Institute since 2006. Previously, he conducted research at the University of Cambridge in England, at the Max Planck Institute for Molecular Physiology in Dortmund (Germany) and at the Memorial Sloan Kettering Cancer Center in New York City.
The award ceremony will take place on June 14 at the Biozentrum of the University of Basel.
More
More
The Swiss politician who learnt to live with the effects of thalidomide
This content was published on
Fifty years after a momentous court case over the drug thalidomide, Christian Lohr talks to Swiss public television, SRF. (SRF, swissinfo.ch)
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
The women changing science in Switzerland
This content was published on
For the international day of women in science, four portraits of women who are changing the face of research in Switzerland.
Ukraine war threatens to derail development of new cancer treatments
This content was published on
The war in Ukraine could disrupt hundreds of clinical trials for critical cancer drugs, many of which are being developed by companies in Switzerland.
How the Swiss-based WHO BioHub is preparing for future pandemics
This content was published on
The first WHO BioHub facility, aimed at storing, analysing and quickly sharing viruses and pathogens, will be based at the Spiez lab near Bern.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.